Your browser doesn't support javascript.
loading
Meta-analysis with individual data of functional outcomes following Aquablation for lower urinary tract symptoms due to BPH in various prostate anatomies.
Elterman, Dean; Gilling, Peter; Roehrborn, Claus; Barber, Neil; Misrai, Vincent; Zorn, Kevin C; Bhojani, Naeem; Te, Alexis; Humphreys, Mitch; Kaplan, Steven; Desai, Mihir; Bach, Thorsten.
Afiliação
  • Elterman D; Surgery, University of Toronto, Toronto, Ontario, Canada.
  • Gilling P; Urology, Tauranga Hospital, Tauranga, New Zealand.
  • Roehrborn C; Urology, The University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Barber N; Urology, Frimley Health NHS Foundation Trust, Frimley, Surrey, UK.
  • Misrai V; Urology, Clinique Pasteur, Toulouse, France.
  • Zorn KC; University of Montreal Hospital Center, Universite de Montreal, Montreal, Québec, Canada.
  • Bhojani N; University of Montreal Hospital Center, Universite de Montreal, Montreal, Québec, Canada.
  • Te A; Urology, Weill Cornell Medical College, New York, New York, USA.
  • Humphreys M; Urology, Mayo Clinic Arizona, Scottsdale, Arizona, USA.
  • Kaplan S; Urology, Mount Sinai Medical Center, New York, New York, USA.
  • Desai M; Urology, University of Southern California, Los Angeles, California, USA.
  • Bach T; Urology, Asklepios Westklinikum Hamburg, Hamburg, Hamburg, Germany.
BMJ Surg Interv Health Technol ; 3(1): e000090, 2021.
Article em En | MEDLINE | ID: mdl-35047807
ABSTRACT

OBJECTIVES:

To evaluate functional outcomes following Aquablation in various prostate volume and anatomical subgroups.

DESIGN:

A meta-analysis with individual patient data undergoing Aquablation therapy from four prospective, global, clinical studies that have been conducted with Aquablation; WATER, WATER II, FRANCAIS WATER and OPEN WATER.

SETTING:

Australia, Canada, Lebanon, Germany, New Zealand, UK and the USA.

PARTICIPANTS:

425 men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) with 1-year follow-up.

INTERVENTIONS:

Aquablation therapy is an ultrasound guided, robotically executed waterjet ablative procedure for the prostate. MAIN OUTCOME

MEASURES:

The analyses focus International Prostate Symptom Score (IPSS), uroflowmetry, postoperative Incontinence Severity Index (ISI) and surgical retreatment.

RESULTS:

425 men with prostates ranging in size from 20 to 150 mL underwent Aquablation therapy. The outcomes from the seven questions in the IPSS questionnaire were grouped by the following; prostates <100 mL, prostates ≥100 mL, prostate anatomy with an obstructive median lobe identifed by imaging, and prostate anatomy without an obstructive median lobe. Regardless of subgroup, all outcomes are consistent and demonstrate a significant improvement from baseline. Specifically, improvements in frequency, urgency and nocturia demonstrated bladder function improvement. Patients entering treatment with severe incontinence, ISI score >4, and regardless of prostate size, showed a reduction in incontinence during patient follow-up. Surgical retreatment due to BPH symptoms occurred in 0.7% (95% CI 0.1%-2.0%).

CONCLUSIONS:

Across a variety of prostate anatomies, Aquablation therapy showed remarkable functional improvements following the index procedure. Additionally, men with moderate to severe LUTS/BPH and overactive bladder resulting in urge incontinence showed a reduction in incontinence symptoms postprocedure.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies / Qualitative_research / Systematic_reviews Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies / Qualitative_research / Systematic_reviews Idioma: En Ano de publicação: 2021 Tipo de documento: Article